Idorsia IDIA

SWX: IDIA | ISIN: CH0363463438   5/01/2026
4,060 CHF (-4,58%)
(-4,58%)   5/01/2026

6 januari 2026 · Idorsia initiates a proof-of-concept trial with its oral first-in-class selective CCR6 antagonist · Persbericht

5 januari 2026 · Idorsia’s daridorexant in women during menopausal transition age with insomnia · Persbericht

5 januari 2026 · Idorsia’s JERAYGO (aprocitentan) approved in Canada for the treatment of resistant hypertension · Persbericht

10 december 2025 · New Hypertension publication underscores aprocitentan’s potential in managing hypertension patients with CKD · Persbericht

9 december 2025 · Idorsia’s treatment for insomnia disorder wins the inaugural Prix Galien Bridges Award in the ‘Best Biotechnology & Pharmaceutical Product’ category · Persbericht

10 november 2025 · Idorsia’s aprocitentan improved key prognostic indicators in patients with difficult-to-control hypertension · Persbericht

5 november 2025 · Idorsia to present new aprocitentan insights at ASN Kidney Week & AHA Scientific Sessions · Persbericht

30 oktober 2025 · QUVIVIQ sales up >130% driving Idorsia toward profitability – 9M 2025 results · Persbericht

10 oktober 2025 · Idorsia successfully completes an upsized offering of shares – funding the company to overall profitability · Persbericht

9 oktober 2025 · Idorsia launches an offering of registered shares – to fund the company to overall profitability · Persbericht

22 september 2025 · Global expansion of Idorsia’s QUVIVIQ continues as Simcere launches in China · Persbericht

19 september 2025 · Idorsia’s JERAYGO (aprocitentan) approved in Switzerland for the treatment of resistant hypertension · Persbericht

10 september 2025 · Idorsia shares new analyses of daridorexant for patients with insomnia at World Sleep 2025 · Persbericht

8 september 2025 · Idorsia highlights very low real-world abuse potential of DORA class for insomnia treatment at WSC 2025 · Persbericht

5 september 2025 · Idorsia to collaborate with two leading academic medical centers to launch IMPACT-HTN – a US initiative to transform care for patients with difficult-to-control hypertension · Persbericht

3 september 2025 · Invitation to Idorsia’s aprocitentan (TRYVIO/JERAYGO) investor Q&A webcast and conference call · Persbericht

1 september 2025 · Idorsia furthers the science of sleep and insomnia at World Sleep 2025 · Persbericht

28 augustus 2025 · Idorsia’s TRYVIO – First FDA-approved therapy to target the endothelin pathway for systemic hypertension · Persbericht

27 augustus 2025 · Idorsia successfully completes convertible bonds restructuring · Persbericht

19 augustus 2025 · TRYVIO™ (aprocitentan) now included in ACC/AHA Clinical Practice Guidelines for the treatment of hypertension · Persbericht

Mijn selecties